Sandeep Vaishnavi, MD
Psychiatry · Chapel Hill, NCNPI 1629116801
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,012 of the $26,954 with a category attached, or 70.5%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 79.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $12,873 and has fallen 99.0% since, to $125 in 2025. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $306.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$21K
- Brainsway USA Inc$4K
- Livanova USA, Inc.$581
- Neuronetics, Inc.$275
- Otsuka America Pharmaceutical, Inc.$227
- AbbVie$191
- plus $728 from 12 others
Across 82 payments — averaging $4768.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$284K
- Livanova USA, Inc.$87K
- Acadia Pharmaceuticals Inc$13K
- Jazz Pharmaceuticals Inc.$5K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Consulting fees$19,01271%
- Travel & lodging$2,0558%
- Food & beverage$5,88722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 16 | $21,329 |
| Brainsway USA Inc | 5 | $3,623 |
| Livanova USA, Inc. | 9 | $581 |
| Neuronetics, Inc. | 3 | $275 |
| Otsuka America Pharmaceutical, Inc. | 7 | $227 |
| AbbVie(2 entities) | 14 | $191 |
| Johnson & Johnson | 3 | $152 |
| Sunovion Pharmaceuticals Inc. | 7 | $132 |
| Lundbeck LLC | 7 | $127 |
| Alkermes, Inc. | 3 | $69 |
| Eisai Inc. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Bausch Health US, LLC | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
| Neos Therapeutics, LP | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,954 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Chapel Hill
- David RubinowChapel Hill$211K
- Elizabeth RichardsonChapel Hill$45K
- Diana PerkinsChapel Hill$44K
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.